)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Synektik
Synektik (SNTP) investor relations material
Synektik Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Aug, 2026
Executive summary
Consolidated revenue for 9M FY2025 rose 52% year-over-year to PLN 733.4 million, driven by strong growth in medical equipment and IT solutions sales, as well as maintenance and measurement services.
EBITDA from continuing operations increased 55% to PLN 189.6 million for 9M FY2025.
Net profit from continuing operations rose 61% year-over-year to PLN 138.0 million, with total comprehensive income at PLN 386.4 million, including a non-cash gain from the demerger of PLN 261.3 million.
The Group completed a significant demerger, transferring the cardiotracer project and Center for Research on New Compounds to Syn2bio SA, resulting in a one-time gain and a reduction in equity.
Significant growth in equipment and IT solutions sales, international expansion, and record contract awards.
Financial highlights
Q3 FY2025 revenue reached PLN 292.3 million, up 89% year-over-year.
Q3 FY2025 EBITDA from continuing operations was PLN 71.5 million, up 72% year-over-year.
Q3 FY2025 net profit from continuing operations rose 80% to PLN 55.1 million.
Operating profit (EBIT) for the nine months was PLN 173.8 million, up from PLN 107.5 million year-over-year.
Positive operating cash flow of PLN 141.4 million over 9M FY2025; net cash position of PLN 35.7 million as of June 30, 2026.
Outlook and guidance
Entered final quarter of 2025 with a backlog and active offers totaling PLN 205 million, a 21% year-over-year increase.
Preparations underway for launch of operations in Ukraine and commercial launch of Edison system in Poland.
Management anticipates continued growth in sales of medical equipment, IT, and maintenance services, supported by higher public healthcare investment and an expanding product portfolio.
Expansion in surgical robotics, especially in Poland and new markets such as Ukraine, is expected to drive future results.
Recurring revenue from services and consumables is projected to increase due to a growing installed base and higher device utilization.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Synektik
- Record revenue and profit growth, strong backlog, and Syn2bio spin-off drive positive outlook.SNTP
Q2 2026 - Revenue and EBITDA surged year-over-year, driven by recurring sales and segment expansion.SNTPQ4 2024
- Double-digit revenue and profit growth, record dividend, and strategic expansion initiatives.SNTPQ1 2026
- 9% revenue growth, 24% EBITDA increase, and strategic R&D spin-off highlight strong results.SNTPQ4 2025
- Revenue and EBITDA soared on strong medical equipment and recurring sales, with robust outlook.SNTPQ2 2024
- Revenue up 55% and net profit up 74% year-over-year, with strong growth in all key segments.SNTPQ3 2024
- Recurring and radio-pharmaceutical revenues rose, margins improved, and strategic expansion continued.SNTPQ1 2025
- Recurring revenue growth and margin improvement offset lower sales, supporting future expansion.SNTPQ2 2025
- Q3 revenue up 24% YoY, EBITDA up 31%, with R&D spin-off and strong recurring revenue growth.SNTPQ3 2025
Next Synektik earnings date
Q4 202618 Nov, 2026
Synektik
Next Synektik earnings date
Q4 202618 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Synektik S.A. provides innovative digital solutions for healthcare. The company's products and services help improve doctors' and physicians' efficiency, patient care, productivity and safety at the point of care.